1. Home
  2. APA vs HALO Comparison

APA vs HALO Comparison

Compare APA & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo APA Corporation

APA

APA Corporation

SELL

Current Price

$47.48

Market Cap

15.4B

Sector

Energy

ML Signal

SELL

Logo Halozyme Therapeutics Inc.

HALO

Halozyme Therapeutics Inc.

SELL

Current Price

$97.47

Market Cap

14.8B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
APA
HALO
Founded
1954
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.4B
14.8B
IPO Year
2021
2001

Fundamental Metrics

Financial Performance
Metric
APA
HALO
Price
$47.48
$97.47
Analyst Decision
Hold
Buy
Analyst Count
28
9
Target Price
$50.31
★ $119.89
AVG Volume (30 Days)
★ 5.5M
2.1M
Earning Date
11-04-2026
11-05-2026
Dividend Yield
★ 2.06%
N/A
EPS Growth
★ 75.77
N/A
EPS
★ 5.36
5.12
Revenue
N/A
★ $151,862,000.00
Revenue This Year
$15.78
$35.97
Revenue Next Year
N/A
$14.85
P/E Ratio
★ $9.03
$19.65
Revenue Growth
N/A
N/A
52 Week Low
$23.06
$61.23
52 Week High
$52.96
$134.00

Technical Indicators

Market Signals
Indicator
APA
HALO
Relative Strength Index (RSI) 51.46 24.66
Support Level $34.03 $64.08
Resistance Level $52.96 $111.15
Average True Range (ATR) 1.84 4.73
MACD -0.22 -3.52
Stochastic Oscillator 46.28 0.82

Price Performance

Historical Comparison
APA
HALO

About APA APA Corporation

APA Corp is an independent exploration and production company. It develops and produces crude oil, natural gas, and natural gas liquids. The company's business has oil and gas operations in four segments: Egypt, the North Sea, Suriname, and the U.S. The company generates the majority of its revenue from the U.S. reporting segment. The company also has exploration interests in Uruguay, Alaska, and other international locations.

About HALO Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Share on Social Networks: